novo glp 1 What's next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care

Reflections on the discovery GLP 1 as a satiety hormone: Implications for obesity therapy and future directions European Journal of Clinical Nutrition Healthy weight loss maintenance with exercise, GLP 1 receptor agonist, or both combined followed by one year without treatment: a post treatment analysis of a randomised placebo controlled trial eClinicalMedicine GLP 1 receptor agonists should not be combined with DPP 4 inhibitors, as there is no added glucose lowering benefit beyond that of the GLP 1 RA alone. Both drug classes work through overlapping mechanisms involving Longterm safety and efficacy of glucagonlike peptide1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study Huang 2024 Diabetes, Obesity and Metabolism Semaglutide for Chronic Weight Management in Las Vegas, NV FDA Approves Oral Semaglutide as First GLP 1 Pill for Weight Loss AJMC